Akebia Therapeutics (AKBA) Receivables - Other (2016 - 2026)

Akebia Therapeutics (AKBA) has 11 years of Receivables - Other data on file, last reported at $300000.0 in Q1 2026.

• On a quarterly basis, Receivables - Other fell 80.84% year-over-year to $300000.0 in Q1 2026; TTM through Mar 2026 was $300000.0, a 80.84% decrease from a year earlier, with the FY2025 full-year figure at $2.4 million, up 18.96% from the prior year.
• Receivables - Other for Q1 2026 stood at $300000.0, down from $2.4 million in the prior quarter.
• Over the last five years, Receivables - Other for AKBA reached as high as $56.6 million in Q2 2022 and fell as low as $300000.0 in Q1 2026.
• Historically, Receivables - Other has averaged $7.5 million across 5 years, with a median of $1.9 million in 2024.
• Across the five-year window, Receivables - Other surged 1910.15% in 2022 and tumbled 99.07% in 2023, its largest moves.
• Year by year, Receivables - Other stood at $781000.0 in 2022, then soared by 326.76% to $3.3 million in 2023, then slumped by 45.24% to $1.8 million in 2024, then surged by 31.01% to $2.4 million in 2025, then slumped by 87.45% to $300000.0 in 2026.
• Per Business Quant data, the three most recent Receivables - Other figures were $300000.0 in Q1 2026, $2.4 million in Q4 2025, and $500000.0 in Q3 2025.